REGULATORY
Kaigen Pharma Hit by Suspension Order for Decades of Illicit Manufacturing
The prefectural governments of Osaka and Hokkaido on December 22 ordered Kaigen Pharma to suspend its production and marketing operations for up to 39 days over fraudulent manufacturing practices at one of its plants that have lasted for more than…
To read the full story
Related Article
- Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
February 14, 2024
REGULATORY
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





